AngioDynamics beat on sales and beat on earnings this morning -- sort of. The company reported a smaller-than-expected ...

A Capital Region manufacturer expects to continue growing its revenue over the next year, though its bottom line could take a ...

Fintel reports that on July 16, 2025, Lake Street initiated coverage of AngioDynamics (NasdaqGS:ANGO) with a Buy ...

Full Year 2025 Results Key Financial Results Revenue: US$292.5m (down 3.8% from FY ...

Q4 2025 Earnings Call Transcript July 15, 2025 AngioDynamics, Inc. beats earnings expectations. Reported EPS is $-0.03, expectations were $-0.13. Operator: Good morning, and welcome to the ...

Gain insights into AngioDynamics' Q4 2025 earnings, highlighting 12% revenue growth, international expansion, Med Tech advances, and a strong FY26 outlook.

Analysts estimate that AngioDynamics will report an earnings per share (EPS) of $-0.12. Investors in AngioDynamics are eagerly awaiting the company's announcement, hoping for news of surpassing ...

Piccolo Medical, Inc. (Piccolo), a leading innovator in vascular access technology, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its next ...

AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment ...

Authorities at Tehran's Evin Prison were still attending to the dead and wounded on the evening of June 23 when one of the highest-profile inmates held there, Swedish-Iranian scientist Ahmadreza ...